Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Aware of Challenges in Drug Price Formation in COVID-19-Hit Market: Official
December 4, 2020
- Yescarta Sails through PAFSC Review; Panel Roughly OKs Novartis’ Corrective Measures after Zolgensma Delay
December 4, 2020
- MHLW Hears Independent Monitoring Panel’s Views on “Periodic Reports”; Will Submit Proposal at Next Meeting
December 4, 2020
- Wholesalers’ Deteriorating Earnings Attributed to Compounding Reasons: JPWA
December 3, 2020
- Lilly’s Galcanezumab Clears PAFSC Review, 1st Antibody for Migraine Prevention
December 3, 2020
- Finance Minister Pushed for All-Product Re-Pricing in 2021: CEFP Minutes
December 3, 2020
- Chuikyo Reps Raise No Opposition to Off-Year Re-Pricing, Still Split over Product Scope
December 3, 2020
- MHLW to Issue Notification to Urge Drug Makers’ Prompt Info Provisioning on Supply Shortages
December 3, 2020
- Japan Diet Clears Immunization Bill
December 2, 2020
- Japan’s Volume-Based Generic Share 78.3% in September, Fails to Hit Govt Goal
December 2, 2020
- Average NHI-Market Price Gap at 8.0%: MHLW
December 2, 2020
- Japan’s Healthcare Spend Rises to 43.4 Trillion Yen in FY2018
December 2, 2020
- MHLW Approves Label Expansions for Forxiga, Trelegy, Evrenzo, Cabometyx and More
November 30, 2020
- Ono’s Cancer Cachexia Drug to Finally Come Up for PAFSC Review on Dec. 11
November 30, 2020
- MHLW Says 7,500 Vaccine Freezers for Storage at Minus 20 Degrees C, Presumably for Moderna Shot
November 30, 2020
- CEFP Member Urges Off-Year Re-Pricing for Preferably All Products, At Least 80%
November 30, 2020
- Japan to Set New Generic Target by March-End: Health Minister
November 30, 2020
- ICH to Stick to Urgent Topics with Significant Impact for Now amid COVID-19
November 30, 2020
- Orphan Drug Status Granted for Lilly’s Selpercatinib, 6 More APIs
November 27, 2020
- Japan Diet Expected to Enact Immunization Bill on Dec. 2
November 27, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…